The current price of KTTA is $0.52 — it has decreased by 1.89% since the previous close. Data as of Nov 5, 2026.
KTTA is up 44.85% over the past week, up 14.31% over the past month and down 29.19% over the past year. The price is below its 200-day moving average of $0.6255.
Analysts' average 12-month price target for KTTA is $3.00, which implies 476.92% upside from the current price. Individual estimates range from $3.00 to $3.00.
Of the 1 analyst covering Pasithea Therapeutics Corp., 1 rates it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Pasithea Therapeutics Corp. has a market capitalization of $17.38M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Pasithea Therapeutics Corp. posted a loss of $0.16 per share, in line with the estimate of -$0.16. Upcoming reports are listed in the earnings calendar.
Pasithea Therapeutics Corp. has not paid any dividends over the past year.
In the latest trading session KTTA moved between $0.4744 and $0.536, a range of 11.85% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Pasithea Therapeutics Corp. shows a buy rating today and a neutral rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Pasithea Therapeutics Corp. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks KTTA has traded between $0.281 and $2.06. The current price is 74.76% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.